机构：[1]Department of Ophthalmology & Clinical Center of Optometry, Peking University People’s Hospital, Beijing 100044, China[2]Eye Diseases and Optometry Institute Peking University People’s Hospital, Beijing 100044, China[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China[4]College of Optometry, Peking University Health Science Center, Beijing 100191, China
To evaluate the efficacy of ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma (DCH) in Sturge-Weber syndrome (SWS).A total of 8 patients with DCH in SWS managed with plaque brachytherapy were retrospectively included. Patients were treated with ruthenium-106 plaque therapy (median apex dose: 83 Gy) at the thickest tumor region. On follow-up, we recorded the tumor thickness, the best-corrected visual acuity (BCVA), subretinal fluid (SRF) status, and complications following treatment.At a median follow-up of 43mo, tumor regression was observed in all cases, with a complete resolution of SRF and reduction in tumor-thickness. No radiation complications were recorded during the follow up time.Ruthenium-106 plaque therapy to the thickest portion of the tumor seems to be a useful treatment in patients with DCH in SWS.International Journal of Ophthalmology Press.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区眼科学
最新[2025]版：
大类|4 区医学
小类|3 区眼科学
第一作者：
第一作者机构：[1]Department of Ophthalmology & Clinical Center of Optometry, Peking University People’s Hospital, Beijing 100044, China[2]Eye Diseases and Optometry Institute Peking University People’s Hospital, Beijing 100044, China[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China[4]College of Optometry, Peking University Health Science Center, Beijing 100191, China
通讯作者：
通讯机构：[1]Department of Ophthalmology & Clinical Center of Optometry, Peking University People’s Hospital, Beijing 100044, China[2]Eye Diseases and Optometry Institute Peking University People’s Hospital, Beijing 100044, China[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China[4]College of Optometry, Peking University Health Science Center, Beijing 100191, China[*1]Department of Ophthalmology, Peking University People’s Hospital, No.11 Xizhimen South Avenue, Xicheng District, Beijing 100044, China.
推荐引用方式(GB/T 7714)：
Yu Ying-Ying,Li Xiao-Xin,Liang Jian-Hong.Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome.[J].International Journal of Ophthalmology.2020,13(3):513-517.doi:10.18240/ijo.2020.03.22.
APA：
Yu Ying-Ying,Li Xiao-Xin&Liang Jian-Hong.(2020).Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome..International Journal of Ophthalmology,13,(3)
MLA：
Yu Ying-Ying,et al."Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome.".International Journal of Ophthalmology 13..3(2020):513-517
